Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme
Data Collection
Astrocytoma+22
+ Astrocytoma
+ Astrocytoma
Treatment Study
Summary
Study start date: May 1, 2004
Actual date on which the first participant was enrolled.OBJECTIVES: Primary * Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme. * Compare 6-month progression-free survival in patients treated with these drugs. Secondary * Compare the safety of these drugs in these patients. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral erlotinib\* once daily on day 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: \*Patients treated with enzyme inducing anti-epileptic drugs (EIAEDs) receive a higher dose of erlotinib than patients not receiving any anti-epileptic drugs or EIAEDs. * Arm II: Patients who have not received prior temozolomide are assigned to receive temozolomide. Patients who have received prior temozolomide are assigned to receive carmustine. Patients receive 1 of the following treatment regimens: * Patients receive oral temozolomide\* once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. * Patients receive carmustine IV once daily on days 1-3. Treatment repeats every 56 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. NOTE: \*Chemotherapy-naïve patients receive a higher dose of temozolomide than patients who have received prior adjuvant chemotherapy. Patients are followed every 8 weeks until disease progression and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 100-110 patients (50-55 per treatment arm) will be accrued for this study.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.110 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 120 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed glioblastoma multiforme * Some oligodendroglial elements allowed provided they make up \< 25% of the tumor * Recurrent disease documented by MRI after prior radiotherapy * At least 1 bidimensionally measurable target lesion ≥ 2 cm by MRI * Undergone prior surgery for recurrent primary brain tumor more than 3 months before study entry * Must have a clearly limited target lesion ≥ 2 cm OR evidence of progressive and measurable target lesion OR a second measurable target lesion outside the surgical area PATIENT CHARACTERISTICS: Age * Over 18 Performance status * Karnofsky 70-100% Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm \^3 Hepatic * AST and ALT \< 2.5 times upper limit of normal (ULN) * Bilirubin \< 1.5 times ULN Renal * Creatinine \< 1.5 times ULN Cardiovascular * Clinically normal cardiac function * No ischemic heart disease within the past 12 months * No New York Heart Association grade III or IV cardiac insufficiency * No unstable angina * No arryhthmia Pulmonary * DLCO \> 70% of predicted (for patients randomized to receive erlotinib \[arm I\] or carmustine \[arm II\]) * No history of pulmonary disease that would affect pulmonary function including any of the following: * Chronic bronchopneumopathy * Pleural effusion * Interstitial pnuemonia * Pulmonary lymphangitis Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation * No other malignancy except cone biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer * No psychological, familial, sociological, or geographical factors that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy * No prior HER-targeted agents * No concurrent growth factors for neutrophil count elevation * No concurrent epoetin alfa Chemotherapy * Prior adjuvant temozolomide allowed * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) * No more than 1 prior adjuvant chemotherapy regimen * No prior chemotherapy for recurrent disease Endocrine therapy * Must be on a stable or decreasing dose of corticosteroids for at least 2 weeks before study entry Radiotherapy * See Disease Characteristics * More than 3 months since prior radiotherapy to the brain * No prior high-dose radiotherapy (\> 65 Gy), stereotactic radiosurgery, or internal radiotherapy unless disease recurrence confirmed Surgery * See Disease Characteristics Other * No prior participation in experimental therapies * No concurrent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, troleandomycin, cimetidine, or grapefruit juice) * No concurrent warfarin or other coumarin derivatives * Concurrent low-molecular weight heparin allowed * No other concurrent investigational drugs
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 10 locations
Centre de Lutte Contre le Cancer Georges-Francois Leclerc
Dijon, FranceCentre Regional Rene Gauducheau
Nantes-Saint Herblain, FranceCentre Antoine Lacassagne
Nice, France